Document is current
Any future updates will be listed below
-
Authors
Adam, Casey Erin https://orcid.org/0009-0004-9814-843X
Mufti, Shatha J. https://orcid.org/0009-0008-4079-2037
Martinez, Jhon https://orcid.org/0009-0007-3762-3446
Rogers, Edmond A. https://orcid.org/0000-0002-0617-0719
Dalolio, Martina https://orcid.org/0000-0002-6108-1348
Krishnan, Nikita https://orcid.org/0000-0001-8371-3951
Beauclair, Timothy https://orcid.org/0000-0002-9257-3329
Shi, Riyi https://orcid.org/0000-0002-7297-9428
- License Information
-
More Information
Article History
Received: 3 September 2025
Accepted: 26 January 2026
First Online: 27 April 2026
Declarations
Competing interests: Riyi Shi is the founder and Chief Scientific Officer of Neuro Vigor Therapeutics (NVT). NVT is focused on the commercialization of novel therapies and diagnostics targeting reactive aldehyde species (RAS) pathobiology across multiple clinical indications. Dr. Shi has not received monetary compensation from NVT for his work related to this manuscript and associated projects. Dr. Shi also serves on the editorial boards of several scientific journals: Frontiers in Molecular Neuroscience (Associate Editor), Neural Regeneration Research, Molecular and Cellular Neuroscience, and Brain Multiphysics. There is no known conflict of interest for the remaining authors.
